The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) is a huge mover today! About 885,723 shares traded hands. Ocular Therapeutix Inc (NASDAQ:OCUL) has declined 36.98% since April 14, 2016 and is downtrending. It has underperformed by 41.67% the S&P500.
The move comes after 7 months positive chart setup for the $234.62M company. It was reported on Nov, 16 by Barchart.com. We have $25.78 PT which if reached, will make NASDAQ:OCUL worth $441.09M more.
Ocular Therapeutix Inc (NASDAQ:OCUL) Ratings Coverage
Out of 4 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ocular Therapeutix has been the topic of 8 analyst reports since August 5, 2015 according to StockzIntelligence Inc. Morgan Stanley maintained Ocular Therapeutix Inc (NASDAQ:OCUL) rating on Thursday, April 28. Morgan Stanley has “Overweight” rating and $17 price target. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Friday, October 23 report. The firm has “Overweight” rating by Morgan Stanley given on Tuesday, June 7. On Tuesday, November 15 the stock rating was maintained by RBC Capital Markets with “Outperform”. The firm has “Overweight” rating by Morgan Stanley given on Thursday, February 18. As per Thursday, August 11, the company rating was initiated by JMP Securities. The company was initiated on Wednesday, August 5 by Nomura. Morgan Stanley initiated the shares of OCUL in a report on Thursday, August 13 with “Equal Weight” rating.
According to Zacks Investment Research, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.”
More news for Ocular Therapeutix Inc (NASDAQ:OCUL) were recently published by: Marketwatch.com, which released: “Ocular Therapeutix surges 14% on positive early clinical trial results” on November 14, 2016. Investorplace.com‘s article titled: “Why CSX Corporation (CSX), Ocular Therapeutix Inc (OCUL), and Ulta Salon …” and published on October 13, 2016 is yet another important article.
OCUL Company Profile
Ocular Therapeutix, Inc., incorporated on September 12, 2006, is a biopharmaceutical company. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. The Company’s hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.